CG Oncology Inc.

Contributing Author

Recent Articles by CG Oncology Inc.

May-28	CG Oncology to Present at Upcoming Investor Conferences in June CGON GlobeNewswire
May-19	SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award CGON GlobeNewswire
May-15	CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients CGON GlobeNewswire
May-11	CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC CGON GlobeNewswire
May-08	CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates CGON GlobeNewswire
May-05	CG Oncology to Present at Upcoming Investor Conferences in May CGON GlobeNewswire
Feb-27	CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates CGON GlobeNewswire
Feb-23	CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference CGON GlobeNewswire
Jan-09	CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC CGON +29.26% GlobeNewswire
Jan-06	CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference CGON GlobeNewswire
Dec-18	SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award CGON GlobeNewswire
Dec-05	New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer CGON GlobeNewswire
Nov-26	CG Oncology Announces New Board Member and Board Transition CGON GlobeNewswire
Nov-25	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting CGON GlobeNewswire
Nov-14	CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates CGON +8.61% GlobeNewswire
Sep-05	CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months CGON +6.88% GlobeNewswire
Sep-03	CG Oncology Completes Enrollment in PIVOT-006 CGON GlobeNewswire
Aug-29	CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences CGON GlobeNewswire
Aug-08	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates CGON GlobeNewswire
Jul-29	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals CGON GlobeNewswire
Jun-05	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference CGON GlobeNewswire
May-15	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference CGON GlobeNewswire
May-13	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates CGON GlobeNewswire

CG Oncology Inc.

Recent Articles by CG Oncology Inc.

Upgrade your Finviz experience